Entrada Therapeutics (TRDA) EBITDA (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly EBITDA of -$42.3 million for Q1 2026, down 94.14% year-over-year from -$721.8 million in Q1 2025, and little changed quarter-over-quarter from -$42.2 million in Q4 2025.
Entrada Therapeutics (TRDA) EBITDA (2020 - 2026) Analysis & Trends
Entrada Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$42.3 million for Q1 2026.
- In Q1 2026, EBITDA fell 94.14% year-over-year to -$42.3 million; the TTM figure through Mar 2026 stood at -$178.4 million (down 4443.01% YoY), while the FY2025 annual figure was -$157.9 million, down 435.87% from the prior year.
- EBITDA for Q1 2026 stood at -$42.3 million, roughly flat from -$42.2 million in the prior quarter.
- The five-year high for EBITDA was $53.4 million in Q2 2024, with the low at -$47.1 million in Q3 2025.
- The 5-year median for EBITDA is -$21.8 million (2025), against an average of -$14.9 million.
- The sharpest annual moves came in 2024 and 2025: EBITDA jumped 465.28% in 2024, then plunged 619.41% in 2025.
- Entrada Therapeutics' EBITDA stood at -$25.6 million in 2022, then jumped by 119.18% to $4.9 million in 2023, then tumbled by 219.61% to -$5.9 million in 2024, then slumped by 619.41% to -$42.2 million in 2025, then declined by 0.23% to -$42.3 million in 2026.
- Business Quant data shows TRDA's EBITDA at -$42.3 million in Q1 2026, -$42.2 million in Q4 2025, and -$47.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | -44.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.96 Mn |
| Mar 31, 2026 | -42.30 Mn |
| Dec 31, 2025 | -42.21 Mn |
| Sep 30, 2025 | -47.05 Mn |
| Jun 30, 2025 | -46.85 Mn |
| Mar 31, 2025 | -21.79 Mn |
| Dec 31, 2024 | -5.87 Mn |
| Sep 30, 2024 | -21.66 Mn |
| Jun 30, 2024 | 53.42 Mn |
| Mar 31, 2024 | 21.11 Mn |
| Dec 31, 2023 | 4.91 Mn |
| Sep 30, 2023 | 14.01 Mn |
| Jun 30, 2023 | -16.30 Mn |
| Mar 31, 2023 | -5.78 Mn |
| Dec 31, 2022 | -25.58 Mn |
| Sep 30, 2022 | -25.94 Mn |
| Jun 30, 2022 | -23.58 Mn |
| Mar 31, 2022 | -22.15 Mn |
| Dec 31, 2021 | -18.46 Mn |
| Sep 30, 2021 | -14.36 Mn |